Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Teva To Acquire Ratiopharm | Contract Pharma

What are you searching for?

Sign in
Breaking News

Teva To Acquire Ratiopharm

Teva Pharmaceutical Industries has bid to acquire Germany-based generic drug manufacturer Ratiopharm, for an estimated $5.0 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva Pharmaceutical Industries has bid to acquire Germany-based generic drug manufacturer Ratiopharm, for an estimated $5.0 billion. The acquisition will provide Teva access to Germany’s generics market — the second largest in the world. Teva currently holds fourth place in Germany’s generics market, but the addition of Ratiopharm will put it at #2. Analysts suggest the takeover would move Teva’s global generics market share to around 19%, widening the gap over its closest competitor Novartis’s Sandoz unit, at about 11%.

Shlomo Yanai, Teva’s president and chief executive officer, said, “This is an important acquisition for Teva. This transaction is perfectly aligned with our long-term strategy in which Europe is an important pillar and growth driver. Ratiopharm will provide us with the ideal platform to strengthen our leadership position in key European markets, most notably in Germany, as well as rapidly growing generic markets such as Spain, Italy and France.”

A Teva statement said the company was valuing Ratiopharm’s portfolio of 500 molecules as well as its background in biosimilars, a field where it has several products in late-stage development. The combined company’s 2009 revenues would have been $16.2 billion, and would have 40,000 employees, with 18,000 in Europe. Teva expects to pare out $400 million in operating costs within three years. The transaction is expected to close by the end of 2010.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics